Review Article Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the Old, While We Wait for Something New

Background: The combination of angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic receptor blockers remains the essential component of heart failure (HF) pharmacotherapy. However, individual patient responses to these pharmacotherapies vary widely. The variability in response cannot be explained entirely by clinical characteristics, and genetic variation may play a role. The purpose of this review is to examine our current state of understanding of beta-blocker and ACE inhibitor pharmacogenetics in HF. Methods and Results: Beta-blocker and ACE inhibitor pharmacogenetic studies performed in patients with HF were identified from the Pubmed database from 1966 to July 2011. Thirty beta-blocker and 10 ACE inhibitor pharmacogenetic studies in patients with HF were identified. The ACE deletion variant was associated with greater survival benefit from ACE inhibitors and beta-blockers compared with the ACE insertion. Ser49 in the beta-1 adrenergic receptor, the insertion in the alpha-2C adrenergic receptor, and Gln41 in G-proteinecoupled receptor kinase 5 are associated with greater survival benefit from betablockers, compared with Gly49, the deletion, and Leu41, respectively. However, many of these associations have not been validated. Conclusions: TheHFpharmacogeneticliteratureisstillinitsveryearlystages,buttherearepromisingcandidategenetic variants that may identify which HF patients are most likely to benefit from beta-blockers and ACE inhibitors and patients that may require additional therapies. (J Cardiac Fail 2012;18:338e349)